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A B S T R A C T
Background
Chronic heart failure (CHF) is a leading cause of morbidity and mortality worldwide. Anaemia is a common (12-55%) co-morbid
condition and is associated with worsening symptoms and increased mortality. Anaemia is treatable and can be targeted in the treatment
of patients with CHF. Erythropoiesis-stimulating agents (ESA), supplemented by iron therapy, are used to treat anaemia in chronic
kidney disease and cancer, however safety concerns have been raised in these patients. The clinical benefit and safety of these agents in
CHF remains unclear.
Objectives
To assess the benefits and risks of ESA for CHF patients with anaemia.
Search methods
We searched the Cochrane Central Register of Controlled Trials (The Cochrane Library 2008, Issue 3), MEDLINE (1950 to October
2008), EMBASE (1980 to October 2008) and reference lists of articles. No language restrictions were applied.
Selection criteria
Randomised controlled trials of any ESA, with or without iron therapy, in CHF patients were eligible for inclusion.
Data collection and analysis
Three reviewers independently assessed study quality and extracted data. Original authors were contacted for additional information.
The outcomes of interest were: exercise tolerance, haemoglobin level, New York Heart Association (NYHA) functional class, quality of
life, left-ventricular ejection fraction, B-type natriuretic peptide, CHF-related hospitalisations, all-cause mortality and adverse effects.
Risk ratios (RR) were calculated for dichotomous data and weighted mean difference (WMD) for continuous data.
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Main results
Eleven studies (794 participants) were included. Overall quality of studies was moderate with nine studies being placebo-controlled
but only five double-blinded. Compared to control, ESA treatment significantly improved exercise duration by 96.8 seconds (95% CI
5.2 to 188.4, p=0.04) and 6-minute walk distance by 69.3 metres (95% CI 17.0 to 121.7, p=0.009). Benefit was also noted in terms of
peak VO2 (+2.29 mL/kg/min, p=0.007), NYHA class (-0.73, p<0.001), ejection fraction (+5.8%, p<0.001), B-type natriuretic peptide
(-226.99 pg/mL, p<0.001) and quality-of-life indicators, with a mean increase in haemoglobin of 1.98 g/dL (p<0.0001). There was
also a significantly lower rate of heart failure related hospitalisations (RR 0.62, 95% CI 0.44 to 0.87) and lower all-cause mortality (RR
0.61, 95% CI 0.37 to 0.99). No increase in adverse events with ESA therapy was observed, however studies were of small sample sizes
and limited duration.
Authors’ conclusions
Meta-analysis of small RCTs suggests that ESA treatment in patients with symptomatic CHF and mild anaemia (haemoglobin more
than 10g/dL) can improve anaemia and exercise tolerance, reduce symptoms and have benefits on clinical outcomes. Confirmation
requires well-designed studies with careful attention to dose, haemoglobin treatment target and associated iron therapy.
P L A I N L A N G U A G E S U M M A R Y
Erythropoiesis-stimulating agents for people with chronic heart failure and anaemia
Chronic heart failure is a disorder in which the heart is unable to pump blood and deliver oxygen adequately throughout the body.
Patients with heart failure may also suffer from anaemia, a condition of reduced red blood cells and diminished ability of the blood to
carry oxygen. These patients appear to have worse symptoms and poorer survival and may benefit from additional therapy for their
anaemia. Erythropoiesis-stimulating agents (ESAs) with iron supplements have been used since the 1980s to treat anaemia in chronic
kidney disease and cancer patients. ESAs have the same action as erythropoietin, a hormone that is naturally produced by the kidneys
to increase red blood cell production. This review shows that ESAs improves anaemia, exercise tolerance, quality of life and reduces
symptoms in heart failure patients with a mild anaemia. ESAs may also reduce hospital admission and improve survival. There was
no increase in major side effects in those receiving ESA therapy compared to control over the 2-12 month study period (maximum 12
months) although the effects of treatment over a longer period are not known. More research is needed to clarify the full effects and
safety of ESAs as a treatment for anaemia in these patients.
B A C K G R O U N D
Description of the condition
Chronic heart failure (CHF) affects over 23millionpatientsworld-
wide (Cleland 2001) and is a leading cause of morbidity and mor-
tality. CHF is the end-stage result of common heart disorders in-
cluding coronary artery disease, hypertension, cardiomyopathies
and valvular heart disease, and is characterised by breathlessness,
fatigue and fluid retention (ACC/AHA 2005). As CHF is primar-
ily a disorder of the elderly, an ageing population will therefore
contribute to an increasing prevalence of CHF. Patients frequently
suffer from multiple non-cardiovascular comorbidities including
pulmonary disease, thyroid disease, diabetes, renal insufficiency
and anaemia.
Anaemia has recently been recognised as an important co-mor-
bid condition which could be targeted in the overall manage-
ment of CHF. Definitions of anaemia vary, although the World
Health Organisation defines a haemoglobin level of less than 13.0
grammes per decilitre (g/dL) for men and less than 12.0 g/dL
for women (Blanc 1968). Anaemia is common in CHF patients,
with a prevalence of approximately 30% (Mitchell 2007) depend-
ing on the population studied and the level of haemoglobin con-
sidered. Multiple mechanisms associated with CHF may con-
tribute to anaemia, including haemodilution, chronic kidney dis-
ease (CKD), activation of pro-inflammatory cytokines, and mal-
nutrition (Felker 2004). Anaemia in people with CHF appears to
be associated with worse symptoms, functional status and a poorer
prognosis than in CHF patients without anaemia (Horwich 2002;
Groenveld 2008). However anaemia as a cause of disease progres-
2Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
sion in CHF patients has yet to be established.
Description of the intervention
Routine medical management for CHF involves diuretics, an-
giotensin-converting enzyme (ACE) inhibitors or angiotensin-
receptor blockers (ARBs), beta-blockers, aldosterone antagonists
and digoxin (ACC/AHA 2005). Although these treatments have
reduced morbidity and mortality, overall hospital admissions for
CHF continue to increase (Rosamond 2008) and new therapeutic
pathways are being sought. Anaemia has emerged as a treatable
comorbidity and has the potential to improve the prognosis of
CHF.
Anaemia of chronic disease appears to be the most frequent cause
of anaemia in CHF (Anand 2008) and may benefit from erythro-
poiesis-stimulating agents (ESAs) and iron therapy (Weiss 2005).
ESAs currently available are darbepoetin alfa and two forms of
recombinant human erythropoietin (rHuEPO), epoetin-alfa and
epoetin-beta (Weiss 2005). There are also a range of supplemen-
tary iron preparations including oral iron (Shord 2008) and intra-
venous iron (Peeters 1996).
How the intervention might work
Darbepoetin alfa and rHuEPO have the same mode of action
as endogenous erythropoietin (EPO) and are the first-line treat-
ment for anaemia of CKD (NKF 2006) and cancer (EORTC
2007; ASCO/ASH 2008). Similarly, ESA treatment may im-
prove CHF outcomes by alleviating symptoms associated with
anaemia. Other benefits of ESAs studied in animal models in-
clude promoting cell survival during ischaemia-reperfusion injury
(Parsa 2004) and stimulating blood vessel formation in the fail-
ing heart (Westenbrink 2007). However ESAs have been associ-
ated with adverse outcomes in CKD and cancer patients, with
increased thromboembolic events, hypertension and mortality re-
ported in patients dosed to higher haemoglobin targets (Henke
2003; Phrommintikul 2007; Bennett 2008).
Iron stores should be adequately maintained to ensure effective
erythropoiesis; thus iron supplementation is recommended for pa-
tients with serum ferritin less than 100 mcg/L or serum transferrin
saturation less than 20% (NKF 2006).
Why it is important to do this review
There are currently several strategies to identify and manage mild
anaemia in CHF patients, but there are no definitive studies to
guide clinical care and guidelines are inconclusive (ACC/AHA
2005; ESC 2008). Serious adverse events have reported in cancer
and CKD patients, thus the safety profile of ESAs in CHF pa-
tients requires investigation. Several small randomised trials have
evaluated ESA and iron therapy and larger randomised trials are
ongoing. This review is required to summarise current evidence
and provide clinical guidance while further definitive evidence is
obtained.
O B J E C T I V E S
To assess the benefit and risk of ESAs for chronic heart failure
patients with anaemia.
M E T H O D S




Adult participants (over 18 years) with symptomatic CHF and
anaemia of chronic disease. The definitions of CHF and anaemia
of chronic disease used by each individual study were accepted.
Types of interventions
Any ESA with or without iron supplementation at any dose, du-
ration, or mode of administration, compared to placebo or no
treatment.
Types of outcome measures
Primary outcomes
1. Exercise tolerance as assessed by any functional capacity
test, including treadmill exercise duration, the 6-minute walk
test and peak VO2.
Secondary outcomes
1. Measure of anaemia correction: Change in haemoglobin
(Hb) level.
2. New York Heart Association (NYHA) functional
classification.
3. Quality of life (QoL).
4. Haemodynamic effects: Left ventricular ejection fraction
(LVEF).
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5. Disease progression: CHF-related hospital admissions and
B-type natriuretic peptide (BNP).
6. All-cause mortality.
7. Adverse effects of specific interest including hypertension,
stroke, myocardial infarction, and other thromboembolic effects.
Search methods for identification of studies
Electronic searches
An electronic search for relevant trials without language restriction
was conducted on The Cochrane Central Register of Controlled
Trials, Health Technology Assessment Database, Database of Ab-
stracts of Reviews of Effect and the NHS Economic Evaluation
Database of The Cochrane Library (2008, Issue 3), MEDLINE
(1950 to October 2008) and EMBASE (1980 to October 2008).
The search strategies are listed in Appendix 1.
Searching other resources
Other resources included the reference lists of each identified study,
other reviews, existing bibliographies and registers of ongoing trials
including:
• Current Controlled Trials (www.controlled-trials.com)
• Clinical Trials register (www.clinicaltrials.gov)
• Australian New Zealand Clinical Trials Registry (
www.anzctr.org.au)
• World Health Organisation International Clinical Trials
Registry Platform (www.who.int/trialsearch).
Data collection and analysis
Selection of studies
The title and abstracts of studies retrieved by electronic searches
were screened by one reviewer (KN) to determine eligibility for
inclusion. The full text of a study was also considered where the
title and abstract provided inadequate information for selection.
Original authors were contacted for clarification of duplicate re-
ports. Studies identified as potentially eligible were further as-
sessed by several reviewers (DK, LM and MF). Reviewers were
not blinded to authors of the studies. Any disagreements between
reviewers were resolved by discussion.
Data extraction and management
Data extraction was conducted independently by three reviewers
(KN,MF and DK), using a pre-tested data extraction form. Orig-
inal authors were contacted where data were missing or unclear.
When one study outcome was reported with two different analy-
ses (e.g. adjusted versus unadjusted analysis), the unadjusted data
were extracted.
Consensus data were entered into the Cochrane Collaboration
software programReviewManager Version 5.0 (Copenhagen, The
Nordic Cochrane Centre, The Cochrane Collaboration, 2008) for
data analysis.
Assessment of risk of bias in included studies
Quality of included studies was independently assessed by three
reviewers (KN, MF and DK) as part of the data extraction pro-
cess using The Cochrane Collaboration’s ‘risk of bias’ assessment
tool (Higgins 2008a). The tool considers six domains of bias: se-
quence generation, allocation concealment, blinding, incomplete
outcome data, selective outcome reporting and ‘other issues’. For
each domain, the study method was described using verbatim
quotes and judged for adequacy (Yes, No, Unclear). A judgement
of ‘Yes’ indicated low risk of bias, while ‘No’ indicated high risk
of bias. Disagreements of judgement were resolved by discussion.
Sensitivity analyses were undertaken to determine the effects of
study quality stratified by using the risk of bias domains.
Measures of treatment effect
Extracted data were entered into the Review Manager software
and analysed by determining the risk ratio (RR) for dichotomous
data and weighted mean difference (WMD) for continuous data.
Ninety-five per cent confidence intervals (95% CI) and p-values
were derived for all comparisons. In the text of this review, results
are presented as WMD, 95% CI or RR, 95% CI unless stated
otherwise.
Dealing with missing data
Original authors were contacted to obtain unreported data on
study design, participant characteristics and selected outcome
data. Whenmissingdata could not be obtained, imputationmeth-
ods were used. Standard deviations (SD) for the end-of-study
mean haemoglobin levels were imputed for two studies. One re-
ported ‘change in haemoglobin level’ as median and interquartile
ranges (IQR) (Ghali 2008). Given that the authors stated “data
was approximately normally distributed” and the sample size was
sufficiently large, the SD was imputed using the following for-
mula: SD = IQR /1.35 (Higgins 2008b). The imputed SD was
consistent with other studies. The other study (Cosyns 2008)
did not provide SDs for the control group and we made the as-
sumption that the SD for both control and ESA group were the
same. Sensitivity analyses were later conducted to assess the effect
of these assumptions.
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Assessment of heterogeneity
For each outcome, a test of heterogeneity was explored using the
Chi-squared test and I2 statistic in the Review Manager software.
The null hypothesis was for no heterogeneity of treatment effect.
The Chi-squared test measures the deviation of observed effect
sizes from an underlying overall effect. This test has low power at
detecting true heterogeneity when studies have small sample size
or are few in number, hence a p-value of 0.10 was used (Deeks
2008). The I2 statistic assesses the impact of heterogeneity on the
meta-analysis. The magnitude is roughly interpreted as:
• 0% to 40%: unimportant;
• 30% to 60%: represents moderate heterogeneity;
• 50% to 90%: represents substantial heterogeneity; and
• 75% to 100%: considerable heterogeneity (Deeks 2008).
Assessment of reporting biases
A funnel plot and Egger’s test was used to check for the presence
of publication bias in analyses with fewer than ten studies (Egger
1997).
Data synthesis
When there was no evidence of statistical heterogeneity and pool-
ing of results was clinically appropriate, a combined estimate was
calculated using the fixed-effect model (Mantel 1959).
When statistically significant heterogeneity (p<0.10) was detected,
several options were followed: the clinical diversity of studies was
explored through pre-specified subgroup analyses comparing the
different types of ESAs (darbepoetin alfa versus rHuEPO), the
random effects model (DerSimonian 1986) was used, or the stud-
ies were not aggregated.
All analyses compared the ESA and control groups using a combi-
nation of endpoints scores or change from baseline scores for each
outcome.
Outcomes assessed as continuous variables were exercise toler-
ance, NYHA class, LVEF, QoL and BNP. Exercise tolerance
was analysed using exercise duration (seconds) and energy expen-
diture (peak VO2 by mL/kg/min) for maximal exercise proto-
cols; and distance walked (metres) for the six-minute walk test
(6MWT). Exercise duration was measured using the treadmill
test and bicycle ergometry. Only results from the same exercise
tolerance measure were combined: all maximal exercise tests and
all 6MWT. Validated QoL instruments considered in the analy-
ses were the Minnesota Living with Heart Failure Questionnaire
(MLHFQ;Rector 1987),KansasCityCardiomyopathyQuestion-
naire (KCCQ;Green 2000) and patient’s global assessment (PGA;
Packer 2002). MLHFQ and KCCQ change from baseline scores
were assessed as separate continuous variables. A higher total score
in the MLHFQ (range= 0 to 105) implies poorer QoL whereas a
higher score in the KCCQ (range= 0 to 100) indicates improved
QoL. PGA was assessed as a dichotomous variable with improve-
ment versus no change or worsening of health status.
Outcomes assessed as dichotomous variables were CHF-related
hospital admissions, all-cause mortality and adverse effects. Ad-
verse effects of specific interest were hypertension, myocardial in-
farction, stroke and other thromboembolic effects, as adjudicated
by the individual studies.
R E S U L T S
Description of studies
Results of the search
The search strategy yielded 568 results. Following screening of
titles and abstracts, the full-text of 23 studies were further evalu-
ated; of these, 11 studies with 794 participants met the inclusion
criteria and one ongoing study was identified (Figure 1). Included
studies were published from 2001 to 2008, the majority of tri-
als were conducted in Europe and four trials declared pharma-
ceutical company sponsorship (Cleland 2005; Ponikowski 2007;
van Veldhuisen 2007; Ghali 2008). Included and ongoing studies
varied in sample size, duration, type of ESA, dosing regime and
supplementary iron therapy. Details of studies included for re-
view are shown in the Characteristics of included studies. Nine
studies were excluded and reasons for exclusion are presented in
the Characteristics of excluded studies. One ongoing study was
identified and details are shown in the Characteristics of ongoing
studies.
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Figure 1. Flow diagram of study selection.
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Included studies
Study design
All studies had a parallel design. One study (Cleland 2005) re-
ported two separate trial protocols of which one (“Study 262”)
had a crossover design. No data from this sub-study was used
in the meta-analysis. Palazzuoli 2006 and Palazzuoli 2007 were
separate studies with different protocols (including different tar-
get haemoglobin anddouble-blind/ open-label follow-upperiods).
Mean study duration was 6.3 (SD 4.1) months, ranging from 2
months to 12 months. Of the 11 studies, three were multicentre
(Ponikowski 2007; van Veldhuisen 2007; Ghali 2008) and the re-
maining eight were conducted at a single institution. Control arm
was typically placebo with two studies (Silverberg 2001; Cosyns
2008) comparing ESA with no treatment.
Trial size
The largest trial (Ghali 2008) was a multicentre parallel study with
319 patients randomised to receive darbepoetin alfa or placebo.
The smallest study recruited 15 patients (Mancini 2003).
Study population
All participants had symptomatic CHF, left ventricular (LV) sys-
tolic dysfunction (LVEF <40%) and anaemia (Table 1). Over-
all mean age ranged from 65-87 years and data from nine trials
identified that 57% were men. All studies met the NYHA criteria
for symptoms with a predominance of NYHA class III patients.
Three studies included NYHA class I patients (Ponikowski 2007;
van Veldhuisen 2007; Ghali 2008), where the inclusion criteria
stipulated patients with “symptomatic CHF”.
The most common aetiology of CHF was ischaemic heart disease
(coronary heart disease and prior myocardial infarction) followed
by dilated cardiomyopathy and hypertension. Two studies speci-
fied CHF secondary to ischaemic or idiopathic dilated cardiomy-
opathy in their inclusion criteria (Kourea 2008a; Parissis 2008).
Patient co-morbidities were not consistently reported. Severe
valvular disease was an exclusion criterion in four studies (Cleland
2005; Palazzuoli 2006; van Veldhuisen 2007; Ghali 2008).
Participants were clinically stable receiving optimal CHF ther-
apy with resting blood pressure less than 160/100mmHg. In
three studies, participants were treated with maximally tolerated
doses of CHF therapy for six months prior to trial commence-
ment (Silverberg 2001; Palazzuoli 2006; Palazzuoli 2007). Base-
line CHF medication was reported in six studies, including use
of angiotensin-converting enzyme (ACE) inhibitors/ angiotensin
receptor blockers (ARBs) (reported in five studies), beta-blockers
(six studies), diuretics (four studies), digoxin (five studies), potas-
sium-sparing agents (two studies), and vasodilators (two studies).
The majority of participants in each trial were taking ACE in-
hibitors/ARBs and diuretics (range 91-92%). There was variation
in the use of other concomitant medications including beta-block-
ers (range 40-91%), digoxin (range 31-93%), potassium-sparing
agents (range 55-100%) and vasodilators (range 40-88%).
Baseline mean haemoglobin levels of participants ranged from
10.1 to 11.8g/dL. Multiple criteria for anaemia were used (Table
2) and studies attempted to exclude secondary causes of anaemia
including acute or chronic bleeding and vitamin B12, folate lev-
els and iron deficiency. Severe renal dysfunction was generally ex-
cluded, however two studies included patients with renal impair-
ment (mean serum creatinine 2.4 to 2.5mg/dL) (Palazzuoli 2006;
Palazzuoli 2007) and one study included patients with chronic
renal disease (Cosyns 2008). Creatinine clearance was variably re-
ported in five studies using Modification of Diet in Renal Disease
and theCockcroft-Gault formula (Cleland 2005; Palazzuoli 2007;
Ponikowski 2007; van Veldhuisen 2007; Ghali 2008).
ESA intervention
ESAs were administered subcutaneously to all participants but
were titrated to haemoglobin targets ranging from 11.5 to 12g/
dL to 13 to 15g/dL. The type of ESA and dose-regimen used in
the studies varied. Darbepoetin alfa was used in six studies and
rHuEPO in five studies. Darbepoetin alfa starting doses ranged
from 0.75 to 5.0mg/kg. In two darbepoetin alfa studies (Cleland
2005; van Veldhuisen 2007), several dosage arms were compared
to one control group. Although van Veldhuisen 2007 compared
a fixed starting dose of 50µg and weight-based starting dose of
0.75µg/kg with a control group, data from the two treated groups
were combined for the analysis. Cleland 2005 compared three
different dosage arms (2.0, 3.0 and 5.0µg/kg) with control in one
sub-study (“Study 198”), however only data from the 2.0µg/kg
group could be analysed.
Schemes for administration ranged from once every two days to
once every 29 days. Darbepoetin alfa was administered every 14
days (Ponikowski 2007; van Veldhuisen 2007; Ghali 2008), 20
days (Kourea 2008a; Parissis 2008) or 29 days (Cleland 2005). For
rHuEPO, dosing regimes were 4000U weekly (Silverberg 2001),
5000U thrice-weekly (Mancini 2003), or 6000IU twice-weekly
(Palazzuoli 2006; Palazzuoli 2007). Thus, the cumulative weekly
dose for rHuEPO ranged from 4,000U to 15,000U per week.
Iron as a co-intervention
Supplementary iron therapy was provided by all except two stud-
ies (Cleland 2005, Cosyns 2008). Iron was provided as part of
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fixed treatment (Silverberg 2001; Mancini 2003; Palazzuoli 2006;
Palazzuoli 2007; Kourea 2008a; Parissis 2008) or unless base-
line ferritin was more than 800ng/mL (Ponikowski 2007; van
Veldhuisen 2007; Ghali 2008). Of the nine studies providing
iron therapy, one study administered ferric sucrose intravenously
(Silverberg 2001), while the other studies administered iron prepa-
rations orally. One study also prescribed folate (1mg daily) as
an additional co-intervention to the treatment group (Mancini
2003).
Risk of bias in included studies
The individual assessment for each study is shown in the ‘Risk
of bias’ table (see Characteristics of included studies) and chart
(Figure 2). Adequate generation of the randomisation sequence
was found in six studies. In general, concealment of allocation
was poorly reported but was judged to be adequate in five stud-
ies including 77% of the study participants (n= 616). Blinding
was variable: five studies were double-blinded, three studies had
only outcome assessors blinded, two studies did not adequately
report methods and one study was not blinded. Out of the 11
studies, only two studies were not placebo-controlled (Silverberg
2001, Cosyns 2008). Regarding incomplete outcome data, most
of the studies were short term so the loss to follow-up was low.
Withdrawals and associated reasons were reported in five studies.
There was limited evidence of selective outcome reporting. The
four studies that were judged to be inadequate in this domain
had not specified their primary outcomes and one study did not
specify the follow-up period, which ranged from 5 to 12 months
(Silverberg 2001).
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Figure 2. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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Another potential source of bias was imbalance in baseline charac-
teristics between groups. In one study, the ESA group had more
diabetics and less use of beta-blockers than control (van Veldhuisen
2007). In another study, the ESA group had greater distance
on the 6MWT at baseline (405m versus 321m) (Mancini 2003).
However it was difficult to assess the similarity of study groups at
baseline as most studies did not include tests for statistical signif-
icance of baseline differences.
The type of publication also influenced quality of outcome report-
ing. Ten studies were published as full text papers in print jour-
nals and one study was published as a letter to the editor (Cosyns
2008).
Publication bias
Only one meta-analysis could be accurately assessed for funnel
plot asymmetry, as all other comparisons included less than ten
studies. Analysis of data reported for change in haemoglobin level
detected a statistically significant asymmetric distribution of stud-
ies (p=0.042; Figure 3). Thismay suggest that negative results were
underreported, however cautious interpretation of these statistics
should be made in view of the high heterogeneity identified which
may also explain the asymmetry noted (Terrin 2005).




The primary outcome of exercise tolerance was reported in seven
studies including 623 participants (Analysis 1.3).Meta-analyses of
all exercise tolerance outcomes had wide confidence intervals and
a random effects model was applied. Overall, exercise duration
improved by 15% from baseline, distance walked by 19% and
peak VO2 by 12% in those treated with ESAs.
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1.1 Exercise duration
Exercise duration was measured in 362 participants (four studies)
and improved by 96.82 seconds (95%CI 5.22 to 188.42, p=0.04)
compared to placebo.
1.2 Distance on 6MWT
Distance on the 6MWT was measured in 261 participants (four
studies) and the overall weighted mean difference (WMD) was
69.33 metres comparing ESA with control (95% CI 16.99
to121.67, p=0.009).
1.3 Peak VO2
Peak VO2 was measured in 102 participants (three studies) and
improved by 2.29mL/kg/min (95% CI 0.62 to 3.95, p=0.007)
(Analysis 1.4). Sensitivity analysis was carried out excluding one
study (Mancini 2003) that had measured peak VO2 using bicycle
exercise, but this had no significant effect on the pooled analysis.
Peak VO2 at anaerobic threshold was alsomeasured by two studies
(Mancini 2003; Palazzuoli 2006). In 61 participants, the anaero-
bic threshold increased by 2.29mL/kg/min in favour of treatment
(95% CI 0.09 to 5.75, p=0.04).
2. Change in haemoglobin level
All 11 studies reported change in haemoglobin level and 782 par-
ticipants were meta-analysed. There was a clinically and statis-
tically significant increase in haemoglobin level of 1.98g/dL in
participants treated with ESAs (95% CI 1.62 to 2.35, p<0.0001;
Analysis 1.6). Sensitivity analyses excluding studies with imputed
data (Cosyns 2008; Ghali 2008) had no effect on the pooled anal-
ysis.
3. NYHA functional class
Eight studies including 657 participants reported change in
NYHA class from baseline until end of study. There was a sta-
tistically significant improvement in NYHA class, which changed
by -0.73 (95% CI -1.11 to -0.36, p=0.0001), suggesting a reduc-
tion in CHF symptoms in those treated by ESAs (Analysis 1.8).
One study reported change in NYHA class at 4 months and at 12
months (Palazzuoli 2007), however results were similar for both
time periods.
4. Quality of life
Quality of life was assessed by the KCCQ, MLHFQ and PGA.
KCCQ scores were reported by three studies including 247 par-
ticipants. Changes in the overall summary score (WMD 4.60,
95% CI 0.46 to 8.75, p=0.03; Analysis 1.9) and the clinical sum-
mary score were statistically significant (WMD 7.10, 95% CI
2.77 to 11.43, p=0.001; Analysis 1.10). Change in the MLHFQ
total score was reported in three studies including 462 partici-
pants and PGA was reported in four studies including 548 partic-
ipants. Trend towards improvement in MLHFQ was non-signifi-
cant (Analysis 1.11) but the PGA was significantly improved with
RR 1.16 (95% CI 1.02 to 1.32, p=0.02; Analysis 1.12).
5. Disease progression
5.1. LVEF
Five studies including 321 participants reported LVEF, which im-
proved by 5.77% compared to control (95% CI 2.43 to 9.11, p=
0.0007; Analysis 1.13).
5.2. BNP
BNP levels were measured in 203 participants (five studies) and
decreased by 226.99pg/mL compared to control (95%CI -322.68
to -131.29, p<0.00001; Analysis 1.14).
6. CHF-related hospitalisations
Nine studies including 734 participants were analysed. CHF-
related hospitalisation occurred in 48 of 412 participants in the
ESA groups compared to 66 of 322 participants in the control
groups. CHF-related hospitalisation was significantly reduced by
38% with ESA intervention (RR 0.62, 95% CI 0.44 to 0.87, p=
0.005; Analysis 1.15).
7. All-cause mortality
Ten studies including 764 participants identified a significant re-
duction in all-cause mortality associated with ESA treatment; RR
0.61 (95% CI 0.37 to 0.99, p=0.04; Analysis 1.16). Deaths oc-
curred in 25 of 426 participants in the ESA groups compared to
35 of 338 participants in the control groups. Causes of death in-
cluded progressive CHF, sudden death, pneumonia, mitral valve
surgery and ischaemic heart disease.
8. Adverse effects
Adverse effects of specific interest including hypertension, stroke,
myocardial infarction and other thromboembolic effects were rare.
Overall, there were no statistically significant differences between
groups.
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8.1. Hypertension
Nine studies including 741 participants were analysed. Hyper-
tension, as specified by each study, occurred in 18 of 410 partic-
ipants in the ESA groups compared to 12 of 331 participants in
the control groups. An increased relative risk of hypertension was
not statistically significant; RR 1.31 (95% CI 0.67 to 2.54, p=
0.43; Analysis 1.17).
8.2. Stroke
Eight studies including 700 participants were analysed. Incidence
of stroke was reported in 7 of 389 participants in the ESA groups
and 4 of 311 participants in the control groups. There was no
statistically significant increase in risk between groups; RR 1.57
(95% CI 0.52 to 4.70, p=0.42; Analysis 1.18).
8.3. Myocardial infarction
Nine studies including 732 participants were analysed. Incidence
of myocardial infarction was reported in 9 of 410 participants
in the ESA groups and 12 of 322 participants in the control
groups. There was no statistically significant increase in risk be-
tween groups; RR 0.69 (95% CI 0.31 to 1.55, p=0.37; Analysis
1.19).
8.4. Other thromboembolic effects
Nine trials including 741 participants were analysed. Throm-
boembolic events were reported in 4 of 410 participants in the
ESA groups and 6 of 331 participants in the control groups. There
was no statistically significant increase in risk between groups; RR
0.65 (95% CI 0.22 to 1.88, p=0.42; Analysis 1.20).
Heterogeneity
There was substantial heterogeneity between the trials for exercise
tolerancemeasures, change in haemoglobin level,NYHA class and
LVEF (p<0.10, I²>60%). No evidence of heterogeneity was found
for CHF-related hospitalisations, all-cause mortality or adverse
effect outcomes (p>0.10, I² = 0%).
The small number of studies precluded subgroup and sensitiv-
ity analyses for most of the outcomes to explore heterogeneity.
Subgroup analyses comparing types of ESA used was undertaken
for the change in haemoglobin level (Analysis 1.7). Darbepoetin
alfa was used in six studies with 610 participants, which increased
haemoglobin level by 1.74g/dL (95% CI 1.28 to 2.20, p=0.001).
Within this subgroup, substantial heterogeneity remained (Chi²
=16.22, p=0.003, I² =75%) due to one study that showed marked
effect of treatment (Cleland 2005). Recombinant human EPO
was used in five studies with 172 participants and increased hae-
moglobin level by 2.26 g/dL (95% CI 1.71 to 2.81, p<0.0001).
There was little evidence of heterogeneity between trials in the
rHuEPO subgroup (Chi²=3.06, p=0.22, I²=35%).
D I S C U S S I O N
Summary of main results
The principal finding of this systematic review was that improve-
ment of anaemia with ESA treatment in participants with CHF
and mild anaemia was associated with improved LV function, im-
proved exercise tolerance and reduction inCHF symptoms. There
was an overall reduction in clinical outcomes and the treatment
was well tolerated.
This study confirms that ESAs effectively raise haemoglobin levels
in anaemic CHF patients. ESAs are established treatments for
anaemia in chronic kidney disease (CKD) patients and cancer pa-
tients undergoing chemotherapy, based on the evidence of an ab-
solute or relative defect in erythropoietin production. However,
the pathogenesis of anaemia in CHF is multifactorial. Causes of
anaemia implicated in CHF include inflammation, CKD, abso-
lute iron-deficiency, ACE inhibitor use, chronic blood loss, mal-
nutrition and plasma volume overload (Okonko 2004). In this
review we have evaluated the effect of ESAs in patients with CHF
and anaemia without an identifiable secondary cause. The studies
examined excluded patients with low iron indices, folate or vi-
tamin B12 deficiency, serum creatinine greater than 3mg or any
co-morbid conditions known to cause anaemia. All participants
suffered from a ‘mild’ anaemia with baseline haemoglobin levels
ranging from 10.1 to 11.8g/dL, although the criteria for anaemia
varied between trials. Thus ESAs yielded positive haematological
response in the absence of a treatable cause of anaemia.
ESA treatment improved exercise tolerance, which was the pri-
mary outcome of this study. This effect was clinically signficant
across maximal (exercise duration) and submaximal exercise per-
formance (distance on six-minute walk). Exercise duration im-
proved by 96.88 seconds (95% CI 5 to 188, p=0.04). In com-
parison, a meta-analysis investigating ACE inhibition on exercise
duration in CHF patients showed an improvement of 28 seconds
(95% CI 12 to 45, p<0.001; Abdulla 2004). Distance walked im-
proved by 69 metres (95% CI 17 to 122, p=0.009), greater than a
distance of 54 metres considered sufficient for a noticeable func-
tional improvement (Redelmeier 1997). Exercise limitation is a
cardinal symptom in CHFpatients. While routine CHF therapies
confer mortality and morbidity benefits, their effects on exercise
capacity are mixed. ACE inhibitors are known to improve exercise
capacity, but beta-blockers have not demonstrated consistent re-
sults (MacMahon 1997). The effect of ESAs on exercise tolerance
is consistent with raised haemoglobin levels and increased oxy-
gen delivery to the periphery. Similarly, treatment with rHuEPO
in haemodialysis patients improved peak VO2, anaerobic thresh-
old and maximal workload (Mayer 1988; McMahon 1992). This
study also found that ESAs improved symptoms, as evidenced by
a reduction in NYHA functional class. Thus, exercise capacity
changes associated with ESA treatment were reflected by a benefit
in symptoms.
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Quality of life assessed using MLHFQ, KCCQ and PGA was im-
proved with ESA treatment. KCCQ overall summary score and
clinical summary score improved, although a change of five points
is considered clinically significant (Spertus 2005). Treatment ef-
fect using the MLHFQ did not reach statistical significance and
may be explained by lower sensitivity of the MLHFQ compared
to the KCCQ to measuring clinical change (Green 2000). Sev-
eral retrospective studies in CHF patients have reported that lower
haemoglobin levels are associated with lower NYHA class and
poorer QoL (Horwich 2002; Falk 2006; Tin 2006). However,
Kosiborod 2008 found no significant association between change
in haematocrit and KCCQ overall scores after three months in
patients with CHF and mild-moderate anaemia (baseline haema-
tocrit <33-39%). This study investigated CHF patients following
myocardial infarction compared to patients with chronic stable
CHF in our review. The positive effect of ESAs on QoL in cancer
and CKD patients is well-documented (Ross 2003). A Cochrane
review of 3,670 cancer patients found ESAs improved cancer-spe-
cific QoL measures, particularly anaemia-related fatigue (Bohlius
2006a). In haemodialysis patients, disease-specific and generic
QoLmeasures also showed benefit from rHuEPO (Laupacis 1991;
Besarab 1998).
The potential mechanistic benefits of ESAs in CHF patients in-
cluding improved exercise tolerance and LVEF can be compared to
the effects of established treatments inCHF. ESAs increased LVEF
by 5.77% (95% CI 2.43 to 9.11, p=0.0007), which is compara-
ble to results with beta-blockers showing dose-related improve-
ments of 5% to 10% (Bristow 1996; Colucci 1996; MacMahon
1997). Improvement in LVEF was associated with a beneficial
neurohormonal response, assessed by significant reduction of BNP
levels. In CKD patients, anaemia is considered an independent
risk factor for LV hypertrophy (Levin 1999), but controlled trials
investigating the effect of ESAs on regression of hypertrophy have
produced inconsistent results (Foley 2008). The mechanism by
which ESAs benefit cardiac function is not fully understood. In
severe anaemia (haemoglobin less than 10g/dL), neurohormonal
activation causes fluid retention and LV remodeling in the long-
term (Metivier 2000). LV hypertrophy and myocardial cell death
contributes to systolic dysfunction (Anand 1993). In CHF pa-
tients, a retrospective substudy of 69 CHF patients found that a
1g/dL spontaneous increase in haemoglobin level was associated
with a 4.1g/m2 decrease in LV mass although not related to LVEF
(Anand 2004). LVEF is affected by ventricular volumes, preload,
afterload, heart rate and valvular function and these haemody-
namic variables are also affected by anaemia. ESAs may reduce
ventricular loading and prevent structural changes through the
improvement of anaemia and neurohormonal alteration. Further,
the cytoprotective effect of ESAs on myocardial cells and vascular
endothelium demonstrated in animal models deserve further clar-
ification in terms of benefits for the failing myocardium (Maiese
2005; Westenbrink 2007).
For clinical outcomes, ESAs were associated with a reduction in
HF-related hospital admissions by 38% and all-cause mortality by
39% (absolute reduction of 4.5%). Beneficial effects on hospi-
talisation have also been confirmed in a smaller meta-analysis of
seven trials (van der Meer 2009). This is comparable to other HF
treatments with ACE inhibitors lowering the risk of hospital read-
mission by 23% (odds ratio 0·73, 0·63 to 0·85, p<0·0001) and
mortality by 20% (odds ratio 0·80, 0·74-0·87, p<0·0001) (Flather
2000). Treatment with digoxin produces a risk reduction in hos-
pitalisation of 28% (RR 0.72, 0.66 to 0.79, p=0.001), although
digoxin does not confer any mortality benefit (DIG 1997). How-
ever, trials included in this review were not adequately powered, or
of sufficient duration, to evaluate mortality and assessed deaths as
a safety end point. Evidence for all-cause mortality was based on
60 deaths out of 764 participants (7.9%). Nevertheless, benefit
in clinical outcomes associated with improvements in LV function
suggest the observations are not due to chance.
This analysis found no apparent effect on hypertension, stroke,
myocardial infarction or other thromboembolic effects although
our ability to detect a small increase (or decrease) in the hazard
ratio was limited by the small sample size and short-term fol-
low-up. A pooled safety analysis of individual patient data from
three of the included studies using darbepoetin alfa (Ponikowski
2007; van Veldhuisen 2007; Ghali 2008) also showed no differ-
ence in adverse effect profile between treatment and control groups
(Klapholz 2008). Adverse effects noted in cancer and CKD pa-
tients have not been observed in CHF patients and may be related
to the different disease process. Meta-analyses of cancer patients
randomly assigned ESA therapy or placebo for anaemia found
an increased risk of thromboembolic complications by 67% (RR
1.67, 95% CI 1.35 to 2.06, p<0.001; Bohlius 2006), and 1.10-
fold increase in mortality (hazard ratio 1.10, 95% CI 1.01 to
1.20, p=0.03) (Bennett 2008). Similarly, a meta-analysis of 5143
CKD patients treated with rHuEPO to different target haemoglo-
bin levels found increased all-cause mortality (RR 1.17, 95% CI
1.01 to 1.35, p=0.031), arteriovenous access thrombosis (RR 1.34,
95% CI 1.16 to 1.54, p=0.0001) and poorly controlled hyperten-
sion (RR 1.27, 95% CI 1.08 to 1.50, p=0.004) (Phrommintikul
2007). These adverse effects occurred in patients that were dosed
to higher haemogloblin levels of 12-16g/dL compared to lower
targets. Taken together, excess adverse effects were observed in
CKD and cancer trials with higher target haemoglobin levels. The
proposed mechanisms for cardiovascular events is through throm-
botic and hypertensive risk (Taylor 1992). However, a recent ran-
domized placebo-controlled trial of 4038 CKD patients with type
2 diabetes and mild anaemia dosed with darbepoetin alfa to a
target haemoglobin of 13g/dL found an increased risk of stroke
which appeared to be independent of any increase in blood pres-
sure (hazard ratio 1.92, 95% CI 1.38 to 2.68, P<0.001), with no
apparent difference in risk of myocardial infarction, CHF, hospi-
talisation for myocardial ischaemia or mortality between groups
(Pfeffer 2009). Whether adverse effects are related to the higher
haemoglobin target levels, or higher doses of ESA used to achieve
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these targets, has yet to be evaluated in CHF patients.
This review found no excess adverse effects in the treatment group
although included studies had haemoglobin targets ranging from
11.5 to 15g/dL. This may be due to short follow-up time of the
studies and differences between CHF patients compared to renal
and oncology patients (e.g. different comorbidities, concomitant
therapies and aetiology of anaemia). The Reduction of Events
With Darbepoetin Alfa inHeart Failure Trial (RED-HF 2008) is a
multicentre RCT that should inform the debate. RED-HF 2008
will investigate a composite outcome ofmortality and first hospital
admission for worsening CHF in 2,600 CHF patients. Similar to
characteristics of participants in this review, the RED-HF 2008
eligibility criteria for CHF participants are NYHA class II-IV and
LVEF ≤ 40% and anaemia defined by a haemoglobin level of 9-
12g/dL. As the study will titrate the ESA dose to a haemoglobin
level of 13g/dL, the optimal haemoglobin level to be achieved in
anaemic CHF patients has yet to be addressed.
Potential biases in the review process
These findings should be interpreted in light of limitations associ-
ated with meta-analysis. There was heterogeneity of study quality,
with two studies not placebo-controlled (Silverberg 2001; Cosyns
2008). Monitoring or reporting of adverse effects was also limited.
Variation between trials was apparent in terms of characteristics of
participants, interventions and methods.
Although different types of ESAs and dosing regimes were used,
darbepoetin alfa and rHuEPO showed equal efficacy in subgroup
analyses. This is consistent with guidelines in CKD and cancer
that consider a class effect (NKF 2006; ASCO/ASH 2008). ESAs
were used in combination with iron therapy in most included
studies. However the effect of iron supplementation, route of iron
administration (oral versus intravenous) and different iron agents
could not be clarified due to the small number of studies. Al-
though trials of intravenous iron alone have shown positive effects
in CHF patients with transferrin saturation less than 15% (Bolger
2006b; Toblli 2007; Okonko 2008), this analysis included partici-
pants considered iron replete with transferrin saturationmore than
15%. Concomitant iron therapy reduces the dose of ESAs and
prevents functional iron deficiency associated with increased rates
of erythropoiesis in CKD and cancer patients (Auerbach 2004;
NKF 2006). As iron therapy has been associated with adverse
outcomes in patients with high or normal ferritin levels (Weiss
2005), there is a need to clarify when to initiate and cease iron
administration.
These effectswere achievedwith concurrent optimalCHF therapy,
including ACE inhibitors or ARBs and beta-blockers. Established
CHF therapies affecting the renin-angiotensin system have been
implicated in the pathogenesis of anaemia (Tang 2006). However
baselineCHFmedicationwas notwell reported in included studies
andpotential interactions could not be adjusted for in our analyses.
Functional capacity tests varied from maximal (treadmill test, bi-
cycle ergometer) to submaximal tests (6MWT) along with the
outcome measures. Results from treadmill and bicycle testing
were combined in the meta-analyses of exercise duration and peak
VO2. However, treadmill testing yields 10% higher peak VO2
and longer exercise duration than bicycle ergometry (Page 1994;
Kim 1999). Sensitivity analyses showed the statistically significant
effect on exercise duration produced by bicycle was not evident
on treadmill, but peak VO2 results were the same. Within stud-
ies, exercise testing can be affected by psychological factors such
as coaching, encouragement from test personnel and differences
in patient’s tolerability (Guyatt 1985; ESC 2008). Variability in
test conduct across centres may explain the lack of exercise dura-
tion improvement in the largest multicentre study (Ghali 2008).
Information regarding exercise test standardisation was generally
limited and may have introduced bias to results: Ghali 2008 con-
ducted at least two baseline screening tests and assessed level of ex-
ertion using the Borg scale, and Palazzuoli 2006 only included pa-
tients who reached their anaerobic threshold. Distance on 6MWT
was measured in four studies, but only one study reported that
encouragement was not used (Mancini 2003).
Statistical heterogeneity between the trials was apparently substan-
tial. Visual interpretation of forest plots for exercise tolerancemea-
sures, change in haemoglobin and LVEF showed the heterogeneity
was influenced by outliers. Heterogeneity was most substantial
for results of NYHA class (p<0.0001, I2 = 96%) and this may
be explained by inter-observer variability in judgement of NYHA
class (Bennett 2002).
Results were based on published tabulated data. Although a
comprehensive search strategy was conducted, there was evidence
of publication bias in the change in haemoglobin level analysis.
Hence, the true benefit of ESAs to increase haemoglobin levels
may be less than reported and poor response to ESA therapy is a
potential concern. Resistance to ESA therapy has been reported
in 5 to 10% of CKD patients (Johnson 2007) and 40 to 50% of
cancer patients (Beguin 2002). CKD patients requiring higher
doses of ESA have higher levels of inflammatory markers (Smrzova
2005). CHF patients also have high levels of pro-inflammatory
markers (Levine 1990) and resistance to the effect of endogenous
EPO has been suggested. A study of 74 CHF patients (NYHA
class III or IV) found endogenous EPO levels to be higher than ex-
pected for the degree of anaemia present correlating with elevated
levels of C-reactive protein (van derMeer 2008). Moreover, higher
serum EPO levels were associated with increased mortality. Only
one included study measured serum EPO levels in patients and
found elevated levels (Mancini 2003). These associations should
be further researched and resistance to ESA therapy defined in the
CHF setting.
Regarding external validity, participants had stable CHF, although
co-morbidities were variably reported. Themean age of patients in
the studies was over 70 years, similar to the age of CHF patients in
the general population. In contrast, the mean age of participants
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enrolled in ACE inhibitor trials was 61 years (Flather 2000) and
63 years with digoxin (DIG 1997).
The included studies were of short duration and insufficient to
fully assess the effects of ESAs on CHF progression, mortality
risk or adverse effects. Moreover, small sample sizes may have
underpowered the overall effect. Two studies had several treatment
arms (Cleland 2005; van Veldhuisen 2007), resulting in more
participants in the ESA group. Longer-term larger trials of larger
cohorts are required to examine the effect of ESAs on clinical
outcomes.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Despite the limitations of this systematic review, we have found
evidence to suggest that ESAs may improve anaemia and provide
clinical benefits when added to routine CHF therapy to those
in mild to moderately-anaemic patients with symptomatic CHF.
Specifically, ESAs appear to improve exercise tolerance, increase
cardiac function and relieve symptoms when dosed to haemoglo-
bin levels ranging from 11.5 to 15g/dL. There is also evidence
for an apparent reduction in morbidity and mortality, although
confirmation will require trials of greater duration and sample size.
The question of whether ESAs affect the risk of adverse effects in
CHF remains unanswered, although we did not identify any sig-
nificant increase in these outcomes in patients treated with ESAs.
Implications for research
Several questions deserve further investigation. The criteria for
anaemia in CHF should be determined as CHF patients with sub-
normal haemoglobin levels are frequently undetected. As part of
the criteria, an algorithm for the initial evaluation of anaemia in
CHF should be developed, taking into account haemodilution, re-
nal dysfunction and iron-deficiency assessment. There is a need to
determine the mechanisms by which ESAs affect cardiac function,
for example the improvement in anaemia and any direct actions
on cardiomyocytes. Potential for resistance to ESA therapy war-
rants monitoring of baseline parameters (e.g. haemoglobin levels,
iron parameters, inflammatory markers and serum EPO levels) in
future studies to understand the dose-response relationship. The
interaction between ESAs and iron therapy should be quantified
to ensure optimal dosing regimes. In addition, the interaction be-
tween ESA treatment with routine CHFmedication should be ad-
dressed, beginning with clear documentation of concurrent med-
ication and comorbidities. Of considerable importance is clarify-
ing the issues of benefit onmortality and adverse effects. Although
the RED-HF trial should provide answers in terms of effects on
mortality and morbidity, the optimal haemoglobin level for ESA
therapy has yet to be addressed.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Cleland 2005
Methods Two sub-studies (Study 198 and Study 262) were reported in the paper. No data from
Study 262 was used in the meta-analysis due to the crossover design
Study 198: 2 months, randomised, double blind, placebo-controlled, 4-armed; With-
drawals: none
Participants Study 198: 24CHFpatients;mean age: ESA72years, control 74 years;NYHAclass II-IV;
LVEF: ESA 36%, control 28%; Hb: ESA 11.0-12.1g/dL, control 11.5g/dL; Creatinine
clearance: ESA 43-68mL/min, control 41mL/min
Interventions Study 198: Treatment: darbepoetin alfa, 2.0, 3.0 or 5.0µg/kg every month (no target);
Iron administered: none; Control: placebo (no iron)
Outcomes Study 198:
Primary outcomes: pharmacokinetic parameters, change in Hb.
Secondary outcomes: number of adverse events.
Notes Study 198: Single-centred. Only CHF patients were included in the analysis. Data could
only be extracted from the 2.0µg/kg group for the ‘Change in Hb level’ outcome as data
from other dosage groups were not suitable for meta-analysis. Declared pharmaceutical
company sponsorship
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Not reported.
Allocation concealment? Unclear risk Not reported.
Blinding?
Subjective outcomes
Unclear risk Quote: “darbepoetin alfa or placebo on
study days 1 and 29”.
Comment: Placebo controlled.
Incomplete outcome data addressed?
All outcomes
Unclear risk Exclusions and withdrawals not reported.
Free of selective reporting? High risk All outcomes reported in the pre-specified
way. Plasma BNP, LVEF and NYHA class
were measured but not reported in results
Free of other bias? Low risk Appears to be free of other bias.
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Cosyns 2008
Methods 2 months, randomised, controlled, blinding not reported.
Withdrawals: not reported
Participants 28 patients; mean age: 68 years; 61% male
NYHA class: (mean) III-IV
LVEF: ESA 31%, control 30%
Hb: ESA 10.1g/dL, control 10.3g/dL
Creatinine clearance < 45mL/min
Interventions Treatment: erythropoietin
Iron administered: not reported
Control: no treatment
Outcomes Primary outcomes: NYHA class, change in Hb, LV parameters, degree of mitral regur-
gitation
Notes Single-centred, reported as a Letter to the Editor.
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Not reported.
Allocation concealment? High risk Quote: “Fourteen were randomly assigned
to receive EPO therapy and the remaining
14 served as control patients.”
Comment: Probably not done.
Blinding?
Subjective outcomes
Unclear risk Trial was not placebo-controlled and blind-
ing was not reported
Incomplete outcome data addressed?
All outcomes
Unclear risk Withdrawals not reported. Study reported
as a Letter to the Editor
Free of selective reporting? Unclear risk Outcomes not prespecified. Study reported
as a Letter to the Editor
Free of other bias? Unclear risk Study reported as a Letter to the Editor.
Ghali 2008
Methods 52 weeks, randomised, double-blind, placebo-controlled
Withdrawals: Treatment (40), control (44)
Participants 319 patients; mean age: ESA 68 years, control 69 years; 63% male
NYHA class I-IV
LVEF: ESA 35%, control 36%
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Ghali 2008 (Continued)
Hb: ESA 11.5g/dL, control 11.3g/dL
Serum creatinine: ESA 1.5mg/dL, control 1.4mg/dL
Interventions Treatment: darbepoetin alfa, starting dose 0.75µg/kg, every 2 weeks to target Hb of 13-
15g/dL
Iron administered: elemental iron orally, daily
Control: placebo and iron
Outcomes Primary outcomes: exercise duration (treadmill)
Secondary outcomes: NYHA class improvement, quality of life (MLHFQ, PGA), time
to death by any cause or first CHF hospitalisation
Notes Multi-centred. Declared pharmaceutical company sponsorship.
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk Quote: “The randomization scheme was
computer-generated, and stratified by
study center.”




Low risk Quote: “Patients and personnel at the study
site were blinded to the treatment. Darbe-
poetin alfa or matching placebo was pro-
vided in single-dose vials. To maintain the
blind, doses were adjusted in a similar fash-
ion for placebo patients on the basis of
hemoglobin modeling data... To maintain
the blind, daily elemental oral iron was ad-
ministered.”
Incomplete outcome data addressed?
All outcomes
Low risk Withdrawals and reasons reported.
Free of selective reporting? Low risk All outcomes reported in the pre-specified
way.
Free of other bias? Low risk Appears to be free of other bias.
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Kourea 2008a
Methods 3 months, randomised, single-blind, placebo-controlled
Withdrawals: not reported
Participants 41 patients; mean age: ESA 73 years, control 65 years; 76% male
NYHA class II-III
LVEF: ESA 26%, control 28%
Hb: ESA 10.9g/dL, control 11.4g/dL
Serum creatinine: ESA 1.7mg/dL, control 1.7mg/dL
Interventions Treatment: darbepoetin alfa, starting dose 1.5µg/kg, every 20 days to target Hb of 12.
5-14g/dL
Iron administered: iron sulphate 250mg orally, twice daily
Control: placebo and iron
Outcomes Primary outcomes: quality of life (KCCQ, DASI)




Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk Quote: “patients were randomized”.
Comment: Probably done as another study
from the same investigators (Parissis 2008)
describes use of computer randomization.
Allocation concealment? Unclear risk Not reported.
Blinding?
Subjective outcomes
High risk Quote: “single-blind”, “all questionnaires
were evaluated by staff who were blinded to
the treatment status of individual patients”
Comment: Patients were not blinded to
treatment.
Incomplete outcome data addressed?
All outcomes
Unclear risk No attrition and exclusions reported.
Free of selective reporting? Low risk Published report includes all expected out-
comes.
Free of other bias? Low risk Appears to be free of other bias.
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Mancini 2003
Methods 3 months (or until haematocrit 45%), randomized, single blind, placebo-controlled
Withdrawals: 2 (ESA), 1 (control)
Participants 23 patients; mean age: ESA 87 years, control 63 years; 78% male
NYHA class III-IV
LVEF: ESA 24%, control 21%
Hb: ESA 11.0g/dL, control 10.9g/dL
Serum creatinine: ESA 1.6mg/dL, control 1.6mg/dL
Interventions Treatment: erythropoietin, 5000U thrice-weekly to target Hct of 45% and folate 1mg
orally daily
Iron administered: ferrous gluconate 325mg orally, daily
Control: placebo (no iron)
Outcomes Primary outcomes: exercise capacity (bicycle, 6MWT, peak VO2)




Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Not reported.
Allocation concealment? Unclear risk Not reported.
Blinding?
Subjective outcomes
High risk Quote: “at the start of the study each con-
trol subject received an injection of normal
saline. The investigators were not blinded
to the study”
Comment: Single-blind study. Also, con-
trol group did not receive iron or folate
treatment
Incomplete outcome data addressed?
All outcomes
Low risk Withdrawals and reasons reported.
Free of selective reporting? High risk All outcomes reported in the pre-specified
way. However standard deviations of qual-
ity of life scores were not reported
Free of other bias? High risk ESA group had much higher baseline VO2
and distance walked on 6-minute walk test
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Palazzuoli 2006
Methods 12 months, randomized, double blind (3 months), open label (next 9 months), placebo-
controlled
Withdrawals: 0 (ESA), 2 (control)
Participants 38 patients; mean age: ESA 72 years, control 75 years; 61% male
NYHA class III-IV
LVEF: ESA 28.3%, control 28%
Hb: ESA 10.4g/dL, control 10.6g/dL
Serum creatinine: ESA 2.5mg/dL, control 2.4mg/dL
Interventions Treatment: beta-EPO, 6000IU twice-weekly to target Hb of 11.5-12g/dL
Iron administered: ferrous gluconate 300mg orally, daily
Control: placebo and iron
Outcomes Primary outcomes: not specified




Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Patients were randomized but sequence
generation was not reported
Allocation concealment? Low risk Comment: Pharmacy-controlled alloca-




Low risk Quote: “[the control group] received the
oral iron in the same daily dose and sc nor-
mal saline injections twice weekly”, “EPO
and saline injections were similar, and it
was impossible to know which syringes
the patients received. The physicians were
unaware which syringes they used”, “All
physicians performing echocardiographic
and exercise tests were blinded about the
treatment”
However blinding was stopped after initial
3 months.
Incomplete outcome data addressed?
All outcomes
Low risk Withdrawals and reasons reported.
Free of selective reporting? Unclear risk Primary outcomes not specified.
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Palazzuoli 2006 (Continued)
Free of other bias? Low risk Appears to be free of other bias.
Palazzuoli 2007
Methods 12 months, randomized, double blind (4 months), open label (next 8 months), placebo-
controlled
Withdrawals: not reported
Participants 51 patients; mean age: ESA 74 years, control 72 years; 61% male
NYHA class III-IV
LVEF: ESA 30%, control 31%
Hb: ESA 10.4g/dL, control 10.6g/dL
Serum creatinine: ESA 2.5mg/dL, control 2.4mg/dL
Interventions Treatment: beta-EPO, 6000IU twice-weekly to target Hb of 12-12.5g/dL
Iron administered: ferrous gluconate 300mg orally, daily
Control: placebo and iron
Outcomes Primary outcomes: left ventricular dimensions and systolic function
Secondary outcomes: cardiac events (sudden death, hospitalisation, myocardial infarc-
tion), body weight, blood pressure changes, edema development, NYHA class
Notes Single-centred, 23 patients previously participated in Palazzuoli 2006.
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Patients were randomized but sequence
generation was not reported
Allocation concealment? Low risk Comment: Pharmacy-controlled alloca-




Low risk Quote: “[the control group] received oral
iron alone and subcutaneous saline injec-
tions twice weekly”, “physicians were un-
aware which syringes they used”, “echocar-
diographic readers were blinded to the sub-
ject sudy assignment and their laboratory
data”
Incomplete outcome data addressed?
All outcomes
Low risk Two patients were excluded so it is assumed
that all other patient contributed to the
data
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Palazzuoli 2007 (Continued)
Free of selective reporting? Low risk All prespecified outcomes were reported.
Free of other bias? High risk Statistical comparisons that are emphasised
are within group and between group com-
parisons for some outcomes are not re-
ported
Parissis 2008
Methods 3 months, randomized, single blind, placebo-controlled
Withdrawals: not reported
Participants 32 patients; mean age: ESA 72 years, control 69 years; unknown% male
NYHA class II-III
LVEF: ESA 26%, control 28%
Hb: ESA 11.0g/dL, control 11.4g/dL
Serum creatinine: ESA 1.7mg/dL, control 1.8mg/dL
Interventions Treatment: darbepoetin alfa, 1.5mg/kg every 20 days to target Hb of 14g/dL
Iron administered: iron sulphate 125mg orally, twice daily
Control: placebo and iron
Outcomes Primary outcomes: LV and RV systolic and diastolic function




Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk Quote: “A computer-generated random-
ization process was followed.”
Allocation concealment? Unclear risk Not reported.
Blinding?
Subjective outcomes
High risk Quote: “Single-blind study...All evalua-
tions were conducted by staff who was
blinded to the treatment status of individ-
ual patients.”
Incomplete outcome data addressed?
All outcomes
Low risk Quote: “5 patients were excluded from the
study because they were unable to perform
a 6MWT, 2 patients were excluded because
they were on NYHA class I, and 2 patients
were excluded because of cancer diagnosis.
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Parissis 2008 (Continued)
”
Comment: Exclusions were reported, attri-
tion was not reported
Free of selective reporting? Low risk All prespecified outcomes were reported.
Free of other bias? Low risk Appears to be free of other bias.
Ponikowski 2007
Methods 26 weeks, randomized, double blind, placebo-controlled
Withdrawals: 3 (ESA), 3 (control)
Participants 41 patients; mean age: ESA 70 years, control 72 years; 54% male
NYHA class I-III
LVEF ≤ 40%
Hb: ESA 11.8g/dL, control 11.6g/dL
Serum creatinine: ESA 1.32mg/dL, control 1.45mg/dL
Interventions Treatment: darbepoetin alfa, 0.75mg/kg every 2 weeks to target Hb of 13-15g/dL
Iron administered: elemental iron 200-300mg orally, daily
Control: placebo and iron
Outcomes Primary outcomes: exercise tolerance (peak VO2 adjusted for body weight)
Secondary outcomes: absolute peakVO2, exercise duration (treadmill),Hb,NYHAclass,
quality of life (KCCQ, MLHFQ, PGA), BNP, body weight, on-study hospitalisations
Notes Multi-centred. Declared pharmaceutical company sponsorship.
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk Quote: “the randomization sequence
which was computer generated”
Allocation concealment? Low risk Quote: “the randomization sequence... was




Low risk Quote: “Patients and personnel at the study
centres were blinded to the identity of the
study drug, hematology results (except at
baseline) and hormone markers. The cen-
tral randomization coordinator calculated
the dose and the volume of drug to be ad-
ministered providing only information on
the volume... central data assessment at the
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Ponikowski 2007 (Continued)
core laboratory.”
Incomplete outcome data addressed?
All outcomes
Low risk Exclusions and withdrawals were reported
with reasons.
Free of selective reporting? High risk All prespecified outcomes were reported.
However, range rather than standard devi-
ation for NYHA class improvement was re-
ported
Free of other bias? Low risk Appears to be free of other bias.
Silverberg 2001
Methods Mean study duration of 8.2 months, randomized, open-label, controlled
Withdrawals: not reported
Participants 32 patients; mean age: ESA 75.3 years, control 72.2 years; 72% male
NYHA class III-IV
LVEF: ESA 30.8%, control 28.4%
Hb: ESA 10.3g/dL, control 10.9g/dL
Serum creatinine: ESA 1.7mg/dL, control 1.4mg/dL
Interventions Treatment: erythropoietin, 4000U weekly to target Hb of >12.5g/dL
Iron administered: ferric sucrose 200mg IV, every 2 weeks
Control: no treatment
Outcomes Primary outcomes: not specified




Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Quote: “patients were randomised consec-
utively into two groups”
Allocation concealment? Unclear risk Not reported.
Blinding?
Subjective outcomes
High risk Control group were not given placebo, pa-
tients were not blinded to treatment
Incomplete outcome data addressed?
All outcomes
Unclear risk Exclusions and attrition not reported.
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Silverberg 2001 (Continued)
Free of selective reporting? High risk Outcomes were not prespecified.
Free of other bias? High risk Follow up period was not specified and
ranged from 5 to 12 months
van Veldhuisen 2007
Methods 26 weeks, randomised, double-blind, placebo-controlled, 3-armed
Withdrawals: 14 (ESA), 7 (control)
Participants 165 patients; mean age: ESA 71 years, control 71 years; 58% male
NYHA class I-IV
LVEF: ESA 29%, control 27%
Hb: ESA 11.5g/dL, control 11.4g/dL
Serum creatinine: ESA 1.4mg/dL, control 1.5mg/dL
Interventions Treatment: darbepoetin alfa, starting dose 0.75µg/kg or 50µg, every 2 weeks to target
Hb of 13-15g/dL
Iron administered: elemental iron 200mg orally, daily
Control: placebo and iron
Outcomes Primary outcomes: rate of rise of Hb (rise/ week)
Secondary outcomes: LVEF, exercise tolerance (6MWT), NYHA class, quality of life
(MLHFQ, KCCQ, PGA)
Notes Multi-centred. Declared pharmaceutical company sponsorship.
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk Quote: “Randomizationwas done centrally
by a computer-generated scheme”
Allocation concealment? Low risk Quote: “Investigators used a central inter-
active voice-response system to obtain a
unique subject number for each subject.”
Blinding?
Subjective outcomes
Low risk Quote: “Patients and personnel were
blinded to investigational product.”
Incomplete outcome data addressed?
All outcomes
Low risk Exclusions and attrition reported.
Free of selective reporting? Low risk All prespecified outcomes were reported.
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van Veldhuisen 2007 (Continued)
Free of other bias? Low risk However large imbalance in diabetes (and
smaller imbalance in beta-blockade)
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Besarab 1998 Parallel-group trial in haemodialysis patients with CHF or ischaemic heart disease randomised to a normal or
subnormal haematocrit target for epoetin alfa therapy
Drueke 2006 Parallel-group trial in chronic kidney disease patients randomised to normal or subnormal Hb levels for epoetin
beta therapy
Kirkpantur 2005 Patients did not haveCHF. RCT on epoetin beta for blood pressure and left ventricular geometry in haemodialysis
patients
Kourea 2008b No outcomes of interest reported.
Li 2004 Patients were not randomised, assigned by alternation.
Silverberg 2000 Uncontrolled trial. First prospective study on treating anaemia in CHF. 26 patients, NYHA IV, were treated with
EPO and IV iron
Silverberg 2003 Uncontrolled trial. Studied EPO and IV iron in 179 diabetic and non-diabetic CHF patients (NYHA III-IV)
with mild-moderate chronic renal failure
Singh 2006 Parallel-group trial in chronic kidney disease patients randomised to high or low Hb targets for epoetin alfa
therapy
Zilberman 2007 Uncontrolled trial on EPO and IV iron for sleep-related breathing disorders in CHF patients
BDI Beck Depression Inventory
BNP B-type natriuretic peptide
CHF chronic heart failure
DASI Duke’s Activity Status Index
EPO erythropoietin
ESA erythropoiesis-stimulating agent




KCCQ Kansas City Cardiomyopathy Questionnaire
LV left ventricular
LVEF left ventricular ejection fraction
mg microgrammes
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mg/dL milligrammes per decilitre
MLHFQ Minnesota Living with Heart Failure Questionnaire
NYHA New York Heart Association
PGA Patient’s Global Assessment
Zung SDS Zung Self-rating Depression Scale
µg/kg microgrammes per kilogramme
6MWT six-minute walk test
Characteristics of ongoing studies [ordered by study ID]
RED-HF 2008
Trial name or title RED-HF Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Methods Randomized, double-blind, placebo-controlled
Participants Estimated enrolment of 2600 patients; eligible age >18 years
NYHA class II-IV, CHF of at least 3 months duration
Hb: 9-12 g/dL
LVEF ≤ 40%
Serum creatinine ≤ 3.0 mg/dL
Interventions Treatment: darbepoetin alfa, starting dose 0.75µg/kg every 2 weeks to target Hb of 13g/dL
Iron administered: not reported
Control: placebo
Outcomes Primary outcomes: composite of time to death from any cause or first hospital admission for worsening CHF
Secondary outcomes: time to death from any cause, time to cardiovascular death or first hospital admission
for worsening CHF (whichever occurs first), quality of life at 6 months (KCCQ)
Starting date June 2006
Contact information Amgen Inc.
Notes Multicentred, phase III trial
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D A T A A N D A N A L Y S E S
Comparison 1. ESA versus control




participants Statistical method Effect size
1 Exercise duration (bike and
treadmill; seconds)
4 362 Mean Difference (IV, Random, 95% CI) 96.82 [5.22, 188.42]
2 Distance on 6-minute walk
(metres)
4 261 Mean Difference (IV, Random, 95% CI) 69.33 [16.99, 121.
67]
3 Exercise tolerance (stratified) 7 Mean Difference (IV, Random, 95% CI) Subtotals only
3.1 Distance on six-minute
walk (metres)




4 362 Mean Difference (IV, Random, 95% CI) 96.82 [5.22, 188.42]
4 Peak VO2 (mL/kg/min) 3 102 Mean Difference (IV, Random, 95% CI) 2.29 [0.62, 3.95]
5 VO2 anaerobic threshold 2 61 Mean Difference (IV, Random, 95% CI) 2.92 [0.09, 5.75]
6 Change in haemoglobin level
(g/dL)
11 782 Mean Difference (IV, Random, 95% CI) 1.98 [1.62, 2.35]
7 Change in haemoglobin level
(g/dL), type of ESA
11 782 Mean Difference (IV, Random, 95% CI) 1.98 [1.62, 2.35]




5 172 Mean Difference (IV, Random, 95% CI) 2.26 [1.71, 2.81]
8 NYHA functional class
improvement
8 657 Mean Difference (IV, Random, 95% CI) -0.73 [-1.11, -0.36]
9 Kansas City Cardiomyopathy
Questionnaire (overall
summary score)
3 247 Mean Difference (IV, Fixed, 95% CI) 4.60 [0.46, 8.75]
10 Kansas City Cardiomyopathy
Questionnaire (clinical
summary score)
3 247 Mean Difference (IV, Fixed, 95% CI) 7.10 [2.77, 11.43]
11 Minnesota Living With Heart
Failure Questionnaire (total
score)
3 462 Mean Difference (IV, Random, 95% CI) -2.02 [-5.78, 1.73]
12 Patient’s Global Assessment
(reported improvement)
4 548 Risk Ratio (M-H, Fixed, 95% CI) 1.16 [1.02, 1.32]
13 LVEF (%) 5 321 Mean Difference (IV, Random, 95% CI) 5.77 [2.43, 9.11]
14 B-type natriuretic peptide
(pg/mL)
5 203 Mean Difference (IV, Fixed, 95% CI) -226.99 [-322.68, -
131.29]
15 CHF-related hospitalisations 9 734 Risk Ratio (M-H, Fixed, 95% CI) 0.62 [0.44, 0.87]
16 All-cause mortality 10 764 Risk Ratio (M-H, Fixed, 95% CI) 0.61 [0.37, 0.99]
17 Adverse effect: hypertension 9 741 Risk Ratio (M-H, Fixed, 95% CI) 1.31 [0.67, 2.54]
18 Adverse effect: stroke 8 700 Risk Ratio (M-H, Fixed, 95% CI) 1.57 [0.52, 4.70]
19 Adverse effect: myocardial
infarction
9 732 Risk Ratio (M-H, Fixed, 95% CI) 0.69 [0.31, 1.55]
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20 Adverse effect: other
thromboembolic effects
9 741 Risk Ratio (M-H, Fixed, 95% CI) 0.65 [0.22, 1.88]
Analysis 1.1. Comparison 1 ESA versus control, Outcome 1 Exercise duration (bike and treadmill; seconds).
Review: Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients
Comparison: 1 ESA versus control
Outcome: 1 Exercise duration (bike and treadmill; seconds)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Ghali 2008 136 57.3 (111.1) 124 45.6 (126.4) 34.7 % 11.70 [ -17.34, 40.74 ]
Palazzuoli 2006 20 468 (150) 18 360 (144) 26.2 % 108.00 [ 14.47, 201.53 ]
Ponikowski 2007 19 597 (235.38) 22 468 (243.902) 18.7 % 129.00 [ -17.93, 275.93 ]
Mancini 2003 15 657 (119) 8 459 (172) 20.4 % 198.00 [ 64.46, 331.54 ]
Total (95% CI) 190 172 100.0 % 96.82 [ 5.22, 188.42 ]
Heterogeneity: Tau2 = 6067.48; Chi2 = 12.02, df = 3 (P = 0.01); I2 =75%
Test for overall effect: Z = 2.07 (P = 0.038)
-100 -50 0 50 100
Favours ESA Favours control
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Analysis 1.2. Comparison 1 ESA versus control, Outcome 2 Distance on 6-minute walk (metres).
Review: Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients
Comparison: 1 ESA versus control
Outcome: 2 Distance on 6-minute walk (metres)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Kourea 2008a 21 274 (97) 20 204 (103) 25.0 % 70.00 [ 8.69, 131.31 ]
Mancini 2003 15 404.77 (77.42) 8 320.65 (122.83) 17.1 % 84.12 [ -9.58, 177.82 ]
Parissis 2008 21 296 (87) 11 167 (99) 22.8 % 129.00 [ 59.67, 198.33 ]
van Veldhuisen 2007 110 34.2 (76.56) 55 11.4 (76.39) 35.1 % 22.80 [ -1.94, 47.54 ]
Total (95% CI) 167 94 100.0 % 69.33 [ 16.99, 121.67 ]
Heterogeneity: Tau2 = 1874.99; Chi2 = 9.94, df = 3 (P = 0.02); I2 =70%
Test for overall effect: Z = 2.60 (P = 0.0094)
-100 -50 0 50 100
Favours control Favours ESA
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Analysis 1.3. Comparison 1 ESA versus control, Outcome 3 Exercise tolerance (stratified).
Review: Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients
Comparison: 1 ESA versus control
Outcome: 3 Exercise tolerance (stratified)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Distance on six-minute walk (metres)
Kourea 2008a 21 274 (97) 20 204 (103) 25.0 % 70.00 [ 8.69, 131.31 ]
Mancini 2003 15 404.77 (77.42) 8 320.65 (122.83) 17.1 % 84.12 [ -9.58, 177.82 ]
Parissis 2008 21 296 (87) 11 167 (99) 22.8 % 129.00 [ 59.67, 198.33 ]
van Veldhuisen 2007 110 34.2 (76.56) 55 11.4 (76.39) 35.1 % 22.80 [ -1.94, 47.54 ]
Subtotal (95% CI) 167 94 100.0 % 69.33 [ 16.99, 121.67 ]
Heterogeneity: Tau2 = 1874.99; Chi2 = 9.94, df = 3 (P = 0.02); I2 =70%
Test for overall effect: Z = 2.60 (P = 0.0094)
2 Exercise duration (seconds)
Ghali 2008 136 57.3 (111.1) 124 45.6 (126.4) 34.7 % 11.70 [ -17.34, 40.74 ]
Mancini 2003 15 657 (119) 8 459 (172) 20.4 % 198.00 [ 64.46, 331.54 ]
Palazzuoli 2006 20 468 (150) 18 360 (144) 26.2 % 108.00 [ 14.47, 201.53 ]
Ponikowski 2007 19 597 (235.38) 22 468 (243.902) 18.7 % 129.00 [ -17.93, 275.93 ]
Subtotal (95% CI) 190 172 100.0 % 96.82 [ 5.22, 188.42 ]
Heterogeneity: Tau2 = 6067.48; Chi2 = 12.02, df = 3 (P = 0.01); I2 =75%
Test for overall effect: Z = 2.07 (P = 0.038)
-200 -100 0 100 200
Favours control Favours ESA
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Analysis 1.4. Comparison 1 ESA versus control, Outcome 4 Peak VO2 (mL/kg/min).
Review: Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients
Comparison: 1 ESA versus control
Outcome: 4 Peak VO2 (mL/kg/min)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Mancini 2003 15 12.7 (2.8) 8 9.5 (1.6) 31.6 % 3.20 [ 1.40, 5.00 ]
Palazzuoli 2006 20 15.1 (2.8) 18 12 (2.5) 33.2 % 3.10 [ 1.41, 4.79 ]
Ponikowski 2007 19 12.4 (2.62) 22 11.7 (2.35) 35.2 % 0.70 [ -0.83, 2.23 ]
Total (95% CI) 54 48 100.0 % 2.29 [ 0.62, 3.95 ]
Heterogeneity: Tau2 = 1.43; Chi2 = 5.96, df = 2 (P = 0.05); I2 =66%
Test for overall effect: Z = 2.69 (P = 0.0071)
-4 -2 0 2 4
Favours control Favours ESA
Analysis 1.5. Comparison 1 ESA versus control, Outcome 5 VO2 anaerobic threshold.
Review: Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients
Comparison: 1 ESA versus control
Outcome: 5 VO2 anaerobic threshold





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Mancini 2003 15 8.7 (1.9) 8 7.1 (0.8) 54.4 % 1.60 [ 0.49, 2.71 ]
Palazzuoli 2006 20 13.2 (3.6) 18 8.7 (2.7) 45.6 % 4.50 [ 2.49, 6.51 ]
Total (95% CI) 35 26 100.0 % 2.92 [ 0.09, 5.75 ]
Heterogeneity: Tau2 = 3.52; Chi2 = 6.12, df = 1 (P = 0.01); I2 =84%
Test for overall effect: Z = 2.02 (P = 0.043)
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Analysis 1.6. Comparison 1 ESA versus control, Outcome 6 Change in haemoglobin level (g/dL).
Review: Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients
Comparison: 1 ESA versus control
Outcome: 6 Change in haemoglobin level (g/dL)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Cleland 2005 6 2.3 (0.6) 6 -0.4 (0.2) 10.0 % 2.70 [ 2.19, 3.21 ]
Cosyns 2008 14 13.1 (0.4) 14 10.2 (0.4) 11.4 % 2.90 [ 2.60, 3.20 ]
Ghali 2008 162 2.1 (1.11) 157 0.5 (1.11) 11.7 % 1.60 [ 1.36, 1.84 ]
Kourea 2008a 21 12.8 (1.4) 20 11.7 (1.5) 7.1 % 1.10 [ 0.21, 1.99 ]
Mancini 2003 15 14.3 (1.2) 8 11.5 (1.3) 5.9 % 2.80 [ 1.71, 3.89 ]
Palazzuoli 2006 20 11.6 (0.4) 18 9.8 (0.5) 11.4 % 1.80 [ 1.51, 2.09 ]
Palazzuoli 2007 26 12.4 (0.8) 25 10.5 (0.6) 10.8 % 1.90 [ 1.51, 2.29 ]
Parissis 2008 21 12.8 (1.3) 11 11.8 (1.3) 6.7 % 1.00 [ 0.05, 1.95 ]
Ponikowski 2007 19 13.9 (1.74) 22 12.3 (1.88) 5.8 % 1.60 [ 0.49, 2.71 ]
Silverberg 2001 16 12.9 (1.1) 16 10.8 (0.8) 8.7 % 2.10 [ 1.43, 2.77 ]
van Veldhuisen 2007 110 13.3 (1.2) 55 11.4 (1.4) 10.5 % 1.90 [ 1.47, 2.33 ]
Total (95% CI) 430 352 100.0 % 1.98 [ 1.62, 2.35 ]
Heterogeneity: Tau2 = 0.28; Chi2 = 66.25, df = 10 (P<0.00001); I2 =85%
Test for overall effect: Z = 10.64 (P < 0.00001)
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Analysis 1.7. Comparison 1 ESA versus control, Outcome 7 Change in haemoglobin level (g/dL), type of
ESA.
Review: Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients
Comparison: 1 ESA versus control
Outcome: 7 Change in haemoglobin level (g/dL), type of ESA





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Darbepoetin alfa
Cleland 2005 6 2.3 (0.6) 6 -0.4 (0.2) 10.0 % 2.70 [ 2.19, 3.21 ]
Ghali 2008 162 2.1 (1.11) 157 0.5 (1.11) 11.7 % 1.60 [ 1.36, 1.84 ]
Kourea 2008a 21 12.8 (1.4) 20 11.7 (1.5) 7.1 % 1.10 [ 0.21, 1.99 ]
Parissis 2008 21 12.8 (1.3) 11 11.8 (1.3) 6.7 % 1.00 [ 0.05, 1.95 ]
Ponikowski 2007 19 13.9 (1.74) 22 12.3 (1.88) 5.8 % 1.60 [ 0.49, 2.71 ]
van Veldhuisen 2007 110 13.3 (1.2) 55 11.4 (1.4) 10.5 % 1.90 [ 1.47, 2.33 ]
Subtotal (95% CI) 339 271 51.7 % 1.74 [ 1.28, 2.20 ]
Heterogeneity: Tau2 = 0.22; Chi2 = 19.98, df = 5 (P = 0.001); I2 =75%
Test for overall effect: Z = 7.38 (P < 0.00001)
2 Recombinant human erythropoietin (epoetin alfa, epoetin beta)
Cosyns 2008 14 13.1 (0.4) 14 10.2 (0.4) 11.4 % 2.90 [ 2.60, 3.20 ]
Mancini 2003 15 14.3 (1.2) 8 11.5 (1.3) 5.9 % 2.80 [ 1.71, 3.89 ]
Palazzuoli 2006 20 11.6 (0.4) 18 9.8 (0.5) 11.4 % 1.80 [ 1.51, 2.09 ]
Palazzuoli 2007 26 12.4 (0.8) 25 10.5 (0.6) 10.8 % 1.90 [ 1.51, 2.29 ]
Silverberg 2001 16 12.9 (1.1) 16 10.8 (0.8) 8.7 % 2.10 [ 1.43, 2.77 ]
Subtotal (95% CI) 91 81 48.3 % 2.26 [ 1.71, 2.81 ]
Heterogeneity: Tau2 = 0.31; Chi2 = 32.05, df = 4 (P<0.00001); I2 =88%
Test for overall effect: Z = 8.07 (P < 0.00001)
Total (95% CI) 430 352 100.0 % 1.98 [ 1.62, 2.35 ]
Heterogeneity: Tau2 = 0.28; Chi2 = 66.25, df = 10 (P<0.00001); I2 =85%
Test for overall effect: Z = 10.64 (P < 0.00001)
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Analysis 1.8. Comparison 1 ESA versus control, Outcome 8 NYHA functional class improvement.
Review: Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients
Comparison: 1 ESA versus control
Outcome: 8 NYHA functional class improvement





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Cosyns 2008 14 2.2 (0.5) 14 3.2 (0.4) 12.2 % -1.00 [ -1.34, -0.66 ]
Ghali 2008 142 -0.19 (0.4767) 128 -0.13 (0.4525) 13.4 % -0.06 [ -0.17, 0.05 ]
Kourea 2008a 21 2.2 (0.4) 20 2.7 (0.5) 12.6 % -0.50 [ -0.78, -0.22 ]
Palazzuoli 2006 20 2.8 (0.5) 18 3.6 (0.4) 12.5 % -0.80 [ -1.09, -0.51 ]
Palazzuoli 2007 26 2.7 (0.5) 25 3.5 (0.5) 12.6 % -0.80 [ -1.07, -0.53 ]
Parissis 2008 21 2.1 (0.5) 11 3.2 (0.6) 11.6 % -1.10 [ -1.51, -0.69 ]
Silverberg 2001 16 2.2 (0.7) 16 3.9 (0.3) 11.9 % -1.70 [ -2.07, -1.33 ]
van Veldhuisen 2007 110 -0.3 (0.6293) 55 -0.23 (0.5933) 13.1 % -0.07 [ -0.27, 0.13 ]
Total (95% CI) 370 287 100.0 % -0.73 [ -1.11, -0.36 ]
Heterogeneity: Tau2 = 0.27; Chi2 = 132.21, df = 7 (P<0.00001); I2 =95%
Test for overall effect: Z = 3.83 (P = 0.00013)
-2 -1 0 1 2
Favours ESA Favours control
41Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.9. Comparison 1 ESA versus control, Outcome 9 Kansas City Cardiomyopathy Questionnaire
(overall summary score).
Review: Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients
Comparison: 1 ESA versus control
Outcome: 9 Kansas City Cardiomyopathy Questionnaire (overall summary score)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Kourea 2008a 21 20 (20) 20 6 (14) 15.5 % 14.00 [ 3.47, 24.53 ]
Ponikowski 2007 19 12.4 (17) 22 10.4 (15.5) 17.1 % 2.00 [ -8.02, 12.02 ]
van Veldhuisen 2007 110 8 (15.73) 55 4.9 (15.57) 67.3 % 3.10 [ -1.96, 8.16 ]
Total (95% CI) 150 97 100.0 % 4.60 [ 0.46, 8.75 ]
Heterogeneity: Chi2 = 3.66, df = 2 (P = 0.16); I2 =45%
Test for overall effect: Z = 2.18 (P = 0.030)
Test for subgroup differences: Not applicable
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Analysis 1.10. Comparison 1 ESA versus control, Outcome 10 Kansas City Cardiomyopathy Questionnaire
(clinical summary score).
Review: Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients
Comparison: 1 ESA versus control
Outcome: 10 Kansas City Cardiomyopathy Questionnaire (clinical summary score)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Kourea 2008a 21 21 (19) 20 2 (11) 21.0 % 19.00 [ 9.55, 28.45 ]
Ponikowski 2007 19 9.6 (15.1) 22 8.6 (17) 19.4 % 1.00 [ -8.83, 10.83 ]
van Veldhuisen 2007 110 8.6 (17.83) 55 3.7 (17.06) 59.6 % 4.90 [ -0.71, 10.51 ]
Total (95% CI) 150 97 100.0 % 7.10 [ 2.77, 11.43 ]
Heterogeneity: Chi2 = 8.17, df = 2 (P = 0.02); I2 =76%
Test for overall effect: Z = 3.22 (P = 0.0013)
Test for subgroup differences: Not applicable
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Analysis 1.11. Comparison 1 ESA versus control, Outcome 11 Minnesota Living With Heart Failure
Questionnaire (total score).
Review: Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients
Comparison: 1 ESA versus control
Outcome: 11 Minnesota Living With Heart Failure Questionnaire (total score)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Ghali 2008 136 -9.3 (18.659) 120 -7.1 (20.813) 59.5 % -2.20 [ -7.07, 2.67 ]
Ponikowski 2007 19 -10.8 (22.1) 22 -13.7 (24.9) 6.8 % 2.90 [ -11.49, 17.29 ]
van Veldhuisen 2007 110 -10.1 (19.9274) 55 -7.4 (20.024) 33.7 % -2.70 [ -9.17, 3.77 ]
Total (95% CI) 265 197 100.0 % -2.02 [ -5.78, 1.73 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.50, df = 2 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 1.05 (P = 0.29)
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Analysis 1.12. Comparison 1 ESA versus control, Outcome 12 Patient’s Global Assessment (reported
improvement).
Review: Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients
Comparison: 1 ESA versus control
Outcome: 12 Patient’s Global Assessment (reported improvement)
Study or subgroup ESA Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ghali 2008 115/162 112/157 71.4 % 1.00 [ 0.87, 1.14 ]
Mancini 2003 12/15 1/8 0.8 % 6.40 [ 1.01, 40.73 ]
Ponikowski 2007 15/19 9/22 5.2 % 1.93 [ 1.11, 3.36 ]
van Veldhuisen 2007 72/110 27/55 22.6 % 1.33 [ 0.99, 1.80 ]
Total (95% CI) 306 242 100.0 % 1.16 [ 1.02, 1.32 ]
Total events: 214 (ESA), 149 (Control)
Heterogeneity: Chi2 = 12.10, df = 3 (P = 0.01); I2 =75%
Test for overall effect: Z = 2.33 (P = 0.020)
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Analysis 1.13. Comparison 1 ESA versus control, Outcome 13 LVEF (%).
Review: Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients
Comparison: 1 ESA versus control
Outcome: 13 LVEF (%)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Kourea 2008a 21 32 (6) 20 28 (8) 19.7 % 4.00 [ -0.34, 8.34 ]
Palazzuoli 2007 26 36.8 (6.5) 25 29.5 (6.1) 22.4 % 7.30 [ 3.84, 10.76 ]
Parissis 2008 21 31 (6) 11 25 (5) 21.0 % 6.00 [ 2.09, 9.91 ]
Silverberg 2001 16 36.3 (11.9) 16 23 (6.9) 13.4 % 13.30 [ 6.56, 20.04 ]
van Veldhuisen 2007 110 1.27 (13.53) 55 -0.02 (6.75) 23.5 % 1.29 [ -1.80, 4.38 ]
Total (95% CI) 194 127 100.0 % 5.77 [ 2.43, 9.11 ]
Heterogeneity: Tau2 = 9.86; Chi2 = 13.50, df = 4 (P = 0.01); I2 =70%
Test for overall effect: Z = 3.38 (P = 0.00072)
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Analysis 1.14. Comparison 1 ESA versus control, Outcome 14 B-type natriuretic peptide (pg/mL).
Review: Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients
Comparison: 1 ESA versus control
Outcome: 14 B-type natriuretic peptide (pg/mL)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Kourea 2008a 21 517 (579) 20 1040 (851) 4.6 % -523.00 [ -970.69, -75.31 ]
Palazzuoli 2006 20 322 (187) 18 538 (246) 46.6 % -216.00 [ -356.11, -75.89 ]
Palazzuoli 2007 26 322 (187) 25 535 (346) 38.9 % -213.00 [ -366.50, -59.50 ]
Parissis 2008 21 661 (858) 11 1212 (821) 2.5 % -551.00 [ -1159.32, 57.32 ]
Ponikowski 2007 19 418.8 (269.4) 22 498.3 (787.6) 7.4 % -79.50 [ -430.20, 271.20 ]
Total (95% CI) 107 96 100.0 % -226.99 [ -322.68, -131.29 ]
Heterogeneity: Chi2 = 3.50, df = 4 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 4.65 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.15. Comparison 1 ESA versus control, Outcome 15 CHF-related hospitalisations.
Review: Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients
Comparison: 1 ESA versus control
Outcome: 15 CHF-related hospitalisations
Study or subgroup ESA Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Cleland 2005 3/18 0/6 1.0 % 2.58 [ 0.15, 43.86 ]
Ghali 2008 25/162 31/157 44.2 % 0.78 [ 0.48, 1.26 ]
Kourea 2008a 3/21 5/20 7.2 % 0.57 [ 0.16, 2.08 ]
Mancini 2003 1/15 4/8 7.3 % 0.13 [ 0.02, 1.00 ]
Palazzuoli 2006 4/20 8/18 11.8 % 0.45 [ 0.16, 1.24 ]
Palazzuoli 2007 4/26 8/25 11.5 % 0.48 [ 0.17, 1.40 ]
Parissis 2008 2/21 3/11 5.5 % 0.35 [ 0.07, 1.79 ]
Ponikowski 2007 2/19 3/22 3.9 % 0.77 [ 0.14, 4.14 ]
van Veldhuisen 2007 4/110 4/55 7.5 % 0.50 [ 0.13, 1.92 ]
Total (95% CI) 412 322 100.0 % 0.62 [ 0.44, 0.87 ]
Total events: 48 (ESA), 66 (Control)
Heterogeneity: Chi2 = 5.35, df = 8 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 2.80 (P = 0.0051)
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Analysis 1.16. Comparison 1 ESA versus control, Outcome 16 All-cause mortality.
Review: Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients
Comparison: 1 ESA versus control
Outcome: 16 All-cause mortality
Study or subgroup ESA Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Cleland 2005 1/18 1/6 3.8 % 0.33 [ 0.02, 4.55 ]
Ghali 2008 11/162 18/157 46.9 % 0.59 [ 0.29, 1.21 ]
Kourea 2008a 1/21 3/20 7.9 % 0.32 [ 0.04, 2.80 ]
Mancini 2003 1/15 0/8 1.6 % 1.69 [ 0.08, 37.26 ]
Palazzuoli 2006 1/20 2/18 5.4 % 0.45 [ 0.04, 4.55 ]
Palazzuoli 2007 3/26 4/25 10.5 % 0.72 [ 0.18, 2.90 ]
Parissis 2008 0/21 2/11 8.3 % 0.11 [ 0.01, 2.09 ]
Ponikowski 2007 1/19 1/22 2.4 % 1.16 [ 0.08, 17.28 ]
Silverberg 2001 0/16 4/16 11.5 % 0.11 [ 0.01, 1.91 ]
van Veldhuisen 2007 6/108 0/55 1.7 % 6.68 [ 0.38, 116.43 ]
Total (95% CI) 426 338 100.0 % 0.61 [ 0.37, 0.99 ]
Total events: 25 (ESA), 35 (Control)
Heterogeneity: Chi2 = 6.68, df = 9 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 2.01 (P = 0.045)
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Analysis 1.17. Comparison 1 ESA versus control, Outcome 17 Adverse effect: hypertension.
Review: Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients
Comparison: 1 ESA versus control
Outcome: 17 Adverse effect: hypertension
Study or subgroup ESA Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Cleland 2005 0/18 0/6 Not estimable
Ghali 2008 13/162 10/157 71.0 % 1.26 [ 0.57, 2.79 ]
Kourea 2008a 1/21 0/20 3.6 % 2.86 [ 0.12, 66.44 ]
Mancini 2003 0/15 0/8 Not estimable
Palazzuoli 2006 0/20 0/18 Not estimable
Palazzuoli 2007 0/26 0/25 Not estimable
Parissis 2008 1/21 0/20 3.6 % 2.86 [ 0.12, 66.44 ]
Ponikowski 2007 1/19 0/22 3.3 % 3.45 [ 0.15, 80.03 ]
van Veldhuisen 2007 2/108 2/55 18.5 % 0.51 [ 0.07, 3.52 ]
Total (95% CI) 410 331 100.0 % 1.31 [ 0.67, 2.54 ]
Total events: 18 (ESA), 12 (Control)
Heterogeneity: Chi2 = 1.77, df = 4 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 0.79 (P = 0.43)
Test for subgroup differences: Not applicable
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Analysis 1.18. Comparison 1 ESA versus control, Outcome 18 Adverse effect: stroke.
Review: Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients
Comparison: 1 ESA versus control
Outcome: 18 Adverse effect: stroke
Study or subgroup ESA Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Cleland 2005 0/18 0/6 Not estimable
Ghali 2008 3/162 3/157 60.3 % 0.97 [ 0.20, 4.73 ]
Kourea 2008a 0/21 0/20 Not estimable
Mancini 2003 0/15 0/8 Not estimable
Palazzuoli 2006 1/20 0/18 10.4 % 2.71 [ 0.12, 62.70 ]
Palazzuoli 2007 2/26 1/25 20.2 % 1.92 [ 0.19, 19.90 ]
Ponikowski 2007 1/19 0/22 9.2 % 3.45 [ 0.15, 80.03 ]
van Veldhuisen 2007 0/108 0/55 Not estimable
Total (95% CI) 389 311 100.0 % 1.57 [ 0.52, 4.70 ]
Total events: 7 (ESA), 4 (Control)
Heterogeneity: Chi2 = 0.74, df = 3 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 0.81 (P = 0.42)
Test for subgroup differences: Not applicable
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Analysis 1.19. Comparison 1 ESA versus control, Outcome 19 Adverse effect: myocardial infarction.
Review: Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients
Comparison: 1 ESA versus control
Outcome: 19 Adverse effect: myocardial infarction
Study or subgroup ESA Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Cleland 2005 0/18 0/6 Not estimable
Ghali 2008 4/162 5/157 36.7 % 0.78 [ 0.21, 2.83 ]
Kourea 2008a 0/21 1/20 11.1 % 0.32 [ 0.01, 7.38 ]
Mancini 2003 0/15 0/8 Not estimable
Palazzuoli 2006 1/20 2/18 15.2 % 0.45 [ 0.04, 4.55 ]
Palazzuoli 2007 2/26 3/25 22.1 % 0.64 [ 0.12, 3.52 ]
Parissis 2008 0/21 0/11 Not estimable
Ponikowski 2007 0/19 1/22 10.1 % 0.38 [ 0.02, 8.89 ]
van Veldhuisen 2007 2/108 0/55 4.8 % 2.57 [ 0.13, 52.60 ]
Total (95% CI) 410 322 100.0 % 0.69 [ 0.31, 1.55 ]
Total events: 9 (ESA), 12 (Control)
Heterogeneity: Chi2 = 1.27, df = 5 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 0.89 (P = 0.37)
Test for subgroup differences: Not applicable
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Analysis 1.20. Comparison 1 ESA versus control, Outcome 20 Adverse effect: other thromboembolic
effects.
Review: Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients
Comparison: 1 ESA versus control
Outcome: 20 Adverse effect: other thromboembolic effects
Study or subgroup ESA Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Cleland 2005 0/18 0/6 Not estimable
Ghali 2008 4/162 3/157 37.6 % 1.29 [ 0.29, 5.68 ]
Kourea 2008a 0/21 1/20 19.0 % 0.32 [ 0.01, 7.38 ]
Mancini 2003 0/15 0/8 Not estimable
Palazzuoli 2006 0/20 0/18 Not estimable
Palazzuoli 2007 0/26 0/25 Not estimable
Parissis 2008 0/21 1/20 19.0 % 0.32 [ 0.01, 7.38 ]
Ponikowski 2007 0/19 0/22 Not estimable
van Veldhuisen 2007 0/108 1/55 24.5 % 0.17 [ 0.01, 4.14 ]
Total (95% CI) 410 331 100.0 % 0.65 [ 0.22, 1.88 ]
Total events: 4 (ESA), 6 (Control)
Heterogeneity: Chi2 = 1.90, df = 3 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 0.80 (P = 0.42)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours ESA Favours control
A D D I T I O N A L T A B L E S
Table 1. Baseline characteristics of study participants.
Study N NYHA
class
Age LVEF (%) Hb (g/dL) Serum creatinine (mg/dL)
Control ESA Control ESA Control ESA Control ESA
Cosyns
2008
28 III-IV 68* 30 31 10.3 10.1 †<45mL/min*
Ghali
2008
319 I-IV 69 68 36 35 11.3 11.5 1.4 1.5
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Table 1. Baseline characteristics of study participants. (Continued)
Kourea
2008a
41 II-III 65 73 28 26 10.4 10.9 1.7 1.7
Parissis
2008




51 III-IV 72 74 31 30 10.6 10.4 2.4 2.5
Ponikowski
2007









38 III-IV 75 72 28 28 10.6 10.4 2.4 2.5
Cleland
2005
24 II-IV 74 69 28 34 11.5 11.8 1.8*
Mancini
2003




32 III-IV 72 75 28 31 10.9 10.3 1.4 1.7
Ranges 63- 87 21- 36 10.1- 11.8 1.4- 2.5
*= groups not specified, †= creatinine clearance
Table 2. Differing criteria for anaemia.











Cosyns 2008 <12g/dL NS NS NS NS NS
Ghali 2008 9-12g/dL Y Y Y Y Y
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Table 2. Differing criteria for anaemia. (Continued)
Kourea 2008a <12.5g/dL Y Y Y Y NS
Parissis 2008 <12.5g/dL Y Y Y Y NS
Palazzuoli 2007 <11.5g/dL Y NS Y Y Y
Ponikowski
2007
9-12g/dL NS Y NS NS NS
van Veldhuisen
2007
9-12g/dL Y Y Y Y Y
Palazzuoli 2006 <11g/dL Y NS Y Y Y
Cleland 2005 <12.5g/dL NS Y Y Y Y
Mancini 2003 <35% NS Y NS NS* NS
Silverberg 2001 10-11.5g/dL Y Y Y Y NS
* = folate administered to patients, NS = not specified, Y = yes
A P P E N D I C E S
Appendix 1. Search strategies
The Cochrane Library
#1 MeSH descriptor heart failure explode all trees
#2 heart next failure in All Text
#3 cardiac next failure in All Text
#4 (#1 or #2 or #3)
#5 MeSH descriptor iron this term only
#6 MeSH descriptor iron compounds explode all trees
#7 MeSH descriptor Erythropoietin explode all trees
#8 MeSH descriptor Hematinics explode all trees
#9 iron in All Text
#10 ferrous in All Text
#11 ferric in All Text
#12 Erythropoiesis in All Text
#13 Erythropoietin in All Text
#14 epoetin in All Text
#15 Darbepoetin in All Text
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#16 erythropoesis in All Text
#17 erythropoetin in All Text
#18 aranesp in All Text
#19 nesp in All Text
#20 epo All Text)
#21 rhuepo in All Text
#22 eprex in All Text
#23 ESA in All Text
#24 ESAs in All Text
#25 anti-anemi* in All Text
#26 anti-anaemi* in All Text
#27 antianemi* in All Text
#28 antianaemi* in All Text
#29 MeSH descriptor anemia explode all trees with qualifiers: TH,DH,DT
#30 darbopoetin in All Text
#31 darbepoietin in All Text
#32 epoietin in All Text
#33 epogen in All Text
#34 eprex in All Text
#35 neorecormon in All Text
#36 recormon in All Text
#37 anemi* in Record Title
#38 anaemi* in Record Title
#39 (#5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14)
#40 (#15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23)
#41 (#24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32)
#42 (#33 or #34 or #35 or #36 or #37 or #38)
#43 (#39 or #40 or #41 or #42)
#44 (#4 and #43)
MEDLINE (Ovid)
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35 4 and 34
36 randomized controlled trial.pt.
37 controlled clinical trial.pt.
38 Randomized controlled trials/
39 random allocation/
40 double blind method/
41 single-blind method/
42 or/36-41
43 exp animal/ not humans/
44 42 not 43
45 clinical trial.pt.
46 exp Clinical Trials as Topic/
47 (clin$ adj25 trial$).ti,ab.






54 53 not 43
55 44 or 54
56 35 and 55
EMBASE (Ovid)
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34 4 and 33
35 controlled clinical trial/
36 random$.tw.
37 randomised controlled trial/
38 follow-up.tw.




43 (crossover$ or cross-over$).ti,ab.
44 (double$ adj blind$).ti,ab.





50 Single Blind Procedure/
51 or/35-50
52 34 and 51
WH A T ’ S N E W
Last assessed as up-to-date: 5 March 2009.
Date Event Description
10 December 2009 Amended Minor typo error corrected in ’Results - Description of studies’ section, under ’CHF-related
hospitalisations’
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